Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Recce PharmaceuticalsASX:RCE +2.78%20 Cash-to-Debt is 0.26 as of Jun. 2026, which is 99% below its 10-year median of 24.74. GuruFocus rates ASX:RCE with a GF Score™ of 20/100. The stock has 4 warning signs investors should review. Among 1,398 Biotechnology companies, Recce Pharmaceuticals ranks worse than 97.85% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Recce Pharmaceuticals's cash to debt ratio for the quarter that ended in Jun. 2026 was 0.26.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Recce Pharmaceuticalscouldn't pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Recce Pharmaceuticals's Cash-to-Debt or its related term are showing as below:
ASX:RCE'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.03 Med: 24.74 Max: No Debt
Current: 0.03
During the past 11 years, Recce Pharmaceuticals's highest Cash to Debt Ratio was No Debt. The lowest was 0.03. And the median was 24.74.
ASX:RCE's Cash-to-Debt is ranked worse than 97.85% of 1398
companies
in the Biotechnology industry
Industry Median: 6.575
vs ASX:RCE: 0.03
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Recce Pharmaceuticals Cash-to-Debt Related Terms
Recce Pharmaceuticals Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Recce Pharmaceuticals's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
ASX:RCE vs VRTX, REGN, MRNA: Cash-to-Debt Comparison
For the Biotechnology subindustry, Recce Pharmaceuticals's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Recce Pharmaceuticals Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Recce Pharmaceuticals's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Recce Pharmaceuticals's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Recce Pharmaceuticals (ASX:RCE) has a Cash-to-Debt of 0.26 as of Jun. 2026. This is 99% below median its historical median of 24.74. Over the past decade, Recce Pharmaceuticals' Cash-to-Debt has ranged from 0.03 to 10,000.00. According to the industry distribution chart, Recce Pharmaceuticals ranks #1368 out of 1398 companies in the Biotechnology industry, placing it in the top 97.9%.
Is Recce Pharmaceuticals' Cash-to-Debt too high?
Recce Pharmaceuticals' current Cash-to-Debt of 0.26 is 99% below median its 10-year median of 24.74. Over the past 10 years, this metric has ranged from a low of 0.03 to a high of 10,000.00. The Biotechnology industry median Cash-to-Debt is 6.58. Recce Pharmaceuticals' value of 0.26 is 96% below this industry median. Based on the distribution chart, Recce Pharmaceuticals ranks #1368 out of 1398 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Recce Pharmaceuticals has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Recce Pharmaceuticals' Cash-to-Debt compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Recce Pharmaceuticals ranks #1368 out of 1398 companies for Cash-to-Debt. This places Recce Pharmaceuticals in the lower half of its industry. The industry median Cash-to-Debt is 6.58. Recce Pharmaceuticals' value of 0.26 is 96% below this benchmark. Historically, Recce Pharmaceuticals' own Cash-to-Debt has ranged from 0.03 to 10,000.00 over the past decade. While the company's 10-year median is 24.74 vs. the industry median of 6.58, Recce Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 6.58, based on 1,398 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Recce Pharmaceuticals's current Cash-to-Debt of 0.26 is 96% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 6.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Recce Pharmaceuticals's current Cash-to-Debt is 0.26, which is 99% below median its own 10-year median of 24.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Recce Pharmaceuticals stock overvalued right now?
Recce Pharmaceuticals (ASX:RCE) has a current Cash-to-Debt of 0.26. The current Cash-to-Debt is 0.26, which is 99% below median its 10-year median of 24.74 and 96% below the Biotechnology industry median of 6.58. Recce Pharmaceuticals' overall GF Score™ is 20/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Recce Pharmaceuticals (ASX:RCE), the current Cash-to-Debt is 0.26 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Recce Pharmaceuticals Ltd is an Australia-based, globally-focused biotechnology company that is pioneering the development and commercialisation of a drug discovery and development business commercialising new Classes of synthetic anti-infectives with broad-spectrum activity designed to address the urgent health threat of antibiotic-resistant superbugs and emerging viral pathogens. Its patented candidate, RECCE 327, has been developed for the treatment of life-threatening bacterial infections. It has one segment, which is the research and development of pharmaceutical drugs. Geographic segments are Australia, the UK, and the USA, of which the majority of the revenue comes from Australia. It offers antibiotic drugs to treat bacterial infections for Sepsis, Escherichia coli, and Others.
20GF Score
Get the complete analysis for ASX:RCE
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:RCE has been successfully added to your 
